Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02762071 · ClinicalTrials.gov registry record · NA
Liposomal Bupivacaine for Pain Control After Total Shoulder Arthroplasty
A NA study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 108
- Enrollment target
NCT02762071: Completed NA study, sponsored by Johns Hopkins University.
NCT02762071 is a NA study that has completed, run by Johns Hopkins University. The registered enrollment target is 108 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02762071, a NA study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
Study Summary
This study will compare interscalene nerve block versus liposomal bupivacaine (Exparel) for pain control after total shoulder replacements. Each method will be assessed in terms of post operative pain scores, pain medication consumption, length of stay, complications (nerve injuries, hematomas, cardiac/respiratory events) and rate of readmission due to pain. The aims of this study will be achieved through a randomized controlled trial and cost-effectiveness analysis.
Interventions
- DRUG Liposomal bupivacaine
- DRUG Interscalene Nerve Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-04-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02762071
The ClinicalTrials.gov registry entry for NCT02762071 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal bupivacaine is the first listed.
NCT02762071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02762071 about?
NCT02762071 is a clinical study titled "Liposomal Bupivacaine for Pain Control After Total Shoulder Arthroplasty". This study will compare interscalene nerve block versus liposomal bupivacaine (Exparel) for pain control after total shoulder replacements. Each method will be assessed in terms of post operative pain scores, pain medication consumption, length of stay, complications (nerve injuries, hematomas, card...
What is the current status of trial NCT02762071?
This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2016-04. Estimated completion is 2019-04-15.
What interventions are being tested in trial NCT02762071?
The interventions under investigation include: Liposomal bupivacaine (DRUG), Interscalene Nerve Block (DRUG).
Who is sponsoring clinical trial NCT02762071?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.